

Datasheet: HCA234

BATCH NUMBER 1806

Description:	HUMAN ANTI INFLIXIMAB
Specificity:	INFLIXIMAB
Other names:	Remicade®
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD20436
Isotype:	HuCAL Fab monovalent
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	■			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form	A monovalent human recombinant Fab selected from the HuCAL® phage display library, expressed in <i>E. coli</i> . The antibody is tagged with a DYKDDDDK tag and a HIS-tag (HHHHHH) at the C-terminus of the antibody heavy chain. This antibody is supplied as a liquid.
Preparation	Metal chelate affinity chromatography
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.01% Thiomersal
Approx. Protein Concentrations	Antibody concentration 0.5 mg/ml
Immunogen	Infliximab.

Specificity **Human anti Infliximab, clone AbD20436**, is an affinity matured anti-idiotypic antibody in monovalent Fab format that specifically recognizes free infliximab but not infliximab bound to its target, Tumor Necrosis Factor Alpha (TNF α). It can be used in bioanalytical assays to measure the levels of infliximab and biosimilar products, such as Inflectra and Renflexis, in patient samples.

Human anti Infliximab, clone AbD20436 inhibits the binding of infliximab to TNF α and can be used as a capture antibody in a pharmacokinetic (PK) assay in the bridging format to measure free drug.

Infliximab (branded as Remicade®) is a chimeric IgG1 kappa monoclonal antibody approved for the treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis. Infliximab is directed against TNF α and acts by blocking the binding of TNF α to its receptors, resulting in a down-regulation of the inflammatory response associated with autoimmune diseases.

[View a summary of all anti-infliximab antibodies.](#)

Affinity	The monovalent intrinsic affinity of this antibody was measured as $K_D=0.12$ nM by real time, label-free molecular interaction analysis on immobilized infliximab.
ELISA	This product may be used in an indirect ELISA system or as a capture reagent in PK assay development together with HRP-conjugated HCA215 or HCA233 as the detection reagent. Protocol: PK bridging ELISA to measure free drug
Storage	Store at +4°C or at -20°C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee	12 months from date of despatch
Acknowledgements	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Remicade® is a registered trademark of Janssen Biotech Inc. Inflectra® is a registered trademark of Hospira, a Pfizer Company. RENFLEXIS™ is a trademark of Merck Sharp & Dohme Corp. His-tag is a registered trademark of EMD Biosciences.
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: https://www.bio-rad-antibodies.com/SDS/HCA234 10094
Licensed Use	For in vitro research purposes and for commercial applications for the provision of in vitro

testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.

Regulatory	For research purposes only
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual

Related Products

Recommended Secondary Antibodies

Goat Anti Synthetic Peptide HISTIDINE TAG (AHP1656...)	Biotin
Rat Anti Synthetic Peptide DYKDDDDK TAG (MCA4764...)	HRP
Mouse Anti Synthetic Peptide HISTIDINE TAG (MCA5995...)	HRP
Rabbit Anti Synthetic Peptide DYKDDDDK TAG (AHP1074...)	HRP
Goat Anti Human IgG F(ab') ₂ (0500-0099...)	HRP
Mouse Anti Synthetic Peptide HISTIDINE TAG (MCA1396...)	Alk. Phos. , Biotin

Recommended Useful Reagents

[HISPEC ASSAY DILUENT \(BUF049A\)](#)
[HUMAN ANTI INFLIXIMAB \(HCA213\)](#)
[HUMAN ANTI INFLIXIMAB \(HCA215\)](#)
[HUMAN ANTI INFLIXIMAB \(HCA233\)](#)
[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)
[RECOMBINANT HUMAN TNF ALPHA \(PHP051\)](#)

North & South America	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com	Worldwide	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com	Europe	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com
----------------------------------	---	------------------	---	---------------	---

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets
'M371658:200612'

Printed on 01 Mar 2024